Ergolin

Ergolin
(IUPAC) ime
	(6aR)-4,6,6a,7,8,9,10,10a-oktahidroindolo [4,3-fg] hinolin
Klinički podaci
Identifikatori
CAS broj	478-88-6
ATC kod	nije dodeljen
PubChem	6857537
ChemSpider	5256873
ChEBI	CHEBI:38484
Hemijski podaci
Formula	C14H16N2
Mol. masa	212,29 g/mol
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C14H16N2/c1-3-11-10-4-2-6-15-13(10)7-9-8-16-12(5-1)14(9)11/h1,3,5,8,10,13,15-16H,2,4,6-7H2/t10-,13-/m1/s1 ; Key: RHGUXDUPXYFCTE-ZWNOBZJWSA-N
Farmakoinformacioni podaci
Trudnoća	?
Pravni status

Ergolin je hemijsko jedinjenje čija strukturna osnova je prisutna u raznovrsnom nizu alkaloida, među kojima su psihodelični lekovi (npr. lizerginska kiselina i LSD).^[4] Derivati ergolina nalaze kliničku primenu kao vazokonstriktori (agonisti 5-HT₁ receptora—ergotamin^[5]) i u lečenju migrene (zajedno sa kofeinom) i Parkinsonove bolesti. Neki ergolinski alkaloidi su nađeni u ergot gljivama i smatra se da su jedan od uzroka ergotizma^[6], koje uzrokuje konvulzivne i gangrenozne simptome.

Reference

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit
↑ Schardl CL, Panaccione DG, Tudzynski P (2006). „Ergot alkaloids – biology and molecular biology”. The Alkaloids: Chemistry and Biology. The Alkaloids: Chemistry and Biology 63: 45-86. DOI:10.1016/S1099-4831(06)63002-2. ISBN 9780124695634. PMID 17133714.
↑ Sanders SW, Haering N, Mosberg H, Jaeger H. Pharmacokinetics of ergotamine in healthy volunteers following oral and rectal dosing. Eur J Clin Pharmacol 1983; 30: 331–4.
↑ Piquemal, R et al (June 1998). „Successful treatment of ergotism with Iloprost--a case report.”. Angiology 49 (6): 493-497.

	Portal Medicina
	Portal Hemija